Proportion of patients with ≥5% weight loss
Time frame · day 0, 180
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
Status
Completed
Phase
Not applicable
Enrollment
175
Locations
14
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
Interventions
Treatment arms and agents.
No intervention details reported.
Timeline
From registration to results.
First posted
Dec 4, 2025
Study start
Nov 11, 2025
Primary completion
Jun 20, 2026
Study completion
Jul 5, 2026
Results posted
Not reported
Registry updated
Jul 15, 2026
Outcomes
What the study measures.
Primary outcomes
Secondary outcomes
Percent change in body weight from baseline
Time frame · day 0, 90
Absolute change in body weight from baseline
Time frame · day 0, 90
Percent change in body weight from baseline
Time frame · day 0, 180
Absolute change in body weight from baseline
Time frame · day 0, 180
Mean change in Body Mass Index from baseline
Time frame · day 0, 90, 180
24.9\<BMI\<30 and more than 30 are considered overweight and obesity, respectively. More BMI decrease is related to the better response.
Mean change in waist circumference from baseline
Time frame · day 0, 90, 180
Proportion of patients with ≥5% weight loss
Time frame · day 0, 90
Proportion of patients with ≥10% weight loss
Time frame · day 0, 90, 180
Proportion of patients with ≥15% weight loss
Time frame · day 0, 180
Assessment of the adverse events (including Treatment Emergent Adverse Events)
Time frame · during study period
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Male or female ≥18 years of age 2. Willingness for signing and having signed the informed consent form 3. BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity Exclusion Criteria: 1. Prior use of any GLP-1 agonist in the last 6 months 2. Type 1 diabetes mellitus 3. Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data 4. Pregnancy or breast-feeding 5. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Study locations
14 registered sites.
Iran. Showing up to 24 locations stored in the fast local snapshot.
Akbar Aliasgarzadeh Clinic
Tabriz, East Azerbaijan Province, Iran
Dr. Mohammadhossein Dabbaghmanesh Clinic
Shiraz, Fars, Iran
Behrang Motamed Clinic
Rasht, Gilan Province, Iran
Seyed Mojtaba Mehrdad Clinic
Rasht, Gilan Province, Iran
Mansoor Siavash Dastjerdi Clinic
Isfahan, Isfahan, Iran
Sari Diabetes Research Center
Sari, Mazandaran, Iran
Shokoofeh Bonakdaran Clininc
Mashhad, Razavi Khorasan Province, Iran
Alireza Esteghamati clinic
Tehran, Tehran Province, Iran
Farzad Hadaegh Clininc
Tehran, Tehran Province, Iran
Imam Khomeini Hospital
Tehran, Tehran Province, Iran
Iran University Endocrinology Research Center
Tehran, Tehran Province, Iran
Mohammadreza Mohajeri Tehrani Clininc
Tehran, Tehran Province, Iran
Khorshid Clinic
Yazd, Yazd Province, Iran
Hajieh Bibi Shahbazian Clinic
Ahvāz, Iran
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Tirzepatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Tirzepatide for Treatment of CCCA
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Tirzepatide in Idiopathic Intracranial Hypertension Trial
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.